BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile

 

TapImmune Inc. 

2815 Eastlake Avenue East
Suite 300
Seattle  Washington  98102  U.S.A.
Phone: 866-359-7541 Fax: n/a


SEARCH JOBS




Industry
Biotechnology

Segment
Oncology
Vaccines





 Company News
TapImmune Inc. (TPIV) Release: Presentation At The Maidstone Life Sciences "Cancer Immunotherapy: A Long-Awaited Reality" 3/31/2015 8:56:34 AM
TapImmune Inc. (TPIV) To Present At The Maidstone Life Sciences "Cancer Immunotherapy: A Long-Awaited Reality" On Thursday March 26, 2015 3/25/2015 9:46:54 AM
TapImmune Inc. (TPIV) Appoints David Laskow-Pooley, CEO Of London Pharma, To Its Board Of Directors 3/19/2015 7:10:20 AM
TapImmune Inc. (TPIV) Receives $1,000,000 From Strategic Investor 3/10/2015 7:06:55 AM
TapImmune Inc. (TPIV) Appoints John Bonfiglio As Strategic Advisor 2/25/2015 9:14:09 AM
TapImmune Inc. (TPIV) Appoints Patrick D. Yeramian, MD, Consulting Medical Director To Lead Phase II Clinical Trials In Triple Negative Breast And HER2/neu Breast Cancer 2/23/2015 9:31:23 AM
TapImmune Inc. (TPIV) To Present At The 3rd Annual Sachs Bio Partnering & Investment Forum On February 23, 2015 2/20/2015 1:33:28 PM
TapImmune Inc. (TPIV)'s CEO Says Company Is Preparing "A Very Deep Pipeline in Multiple Indications" For Phase II Trials 2/12/2015 12:57:46 PM
TapImmune Inc. (TPIV) Announces $1,464,000 Million Registered Direct Offering 1/12/2015 9:27:40 AM
TapImmune Inc. (TPIV) Release: Positive Phase 1 Immune Responses In All Evaluable Ovarian And Breast Cancer Patients Advances Vaccine To Phase 2 Clinical Trials 1/12/2015 8:50:40 AM
123456789